表紙
市場調查報告書

躁鬱症市場 - 成長,趨勢,及預測(2019年 - 2024年)

Bipolar Disorder Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 871392
出版日期 內容資訊 英文 114 Pages
商品交期: 2-3個工作天內
價格
Back to Top
躁鬱症市場 - 成長,趨勢,及預測(2019年 - 2024年) Bipolar Disorder Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年05月01日內容資訊: 英文 114 Pages
簡介

本報告提供全球躁鬱症市場的相關調查,市場概況和成長要素、阻礙因素,各藥物類別、作用機制、地區的市場分析,競爭情形,主要企業的簡介等資訊相關彙整。

目錄

第1章 簡介

  • 研究成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 躁鬱症的罹患率的增加
    • 政府機關提出舉措提高意識
    • 技術的進步
  • 市場阻礙因素
    • 躁鬱症藥相關副作用
    • 躁鬱症的誤診
  • 波特五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各藥物類別
    • 心情穩定劑
    • 抗痙攣藥
    • 抗精神病藥
    • 抗憂鬱症藥
    • 其他
  • 各作用機制
    • 選擇性血清素回收抑制劑
    • 血清素正腎上腺素再回收抑制劑
    • 三環抗憂鬱藥物
    • β受體阻斷劑
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東及非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • AbbVie Inc.
    • Allergan PLC
    • AstraZeneca Plc
    • Eli Lilly and Company
    • GlaxoSmithKline Plc
    • Janssen Pharmaceuticals Inc.
    • Novartis AG
    • Otsuka Holdings Co. Ltd
    • Pfizer Inc.

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 64901

Market Overview

The major factors for the growth of the bipolar disorder market include the increasing prevalence of the bipolar disorder, rising initiatives by government institutes to increase the awareness, and technological advancements.

There is an increasing prevalence of bipolar disorder owing to the various risk factors such as high stress, substance abuse, and others. According to the estimates of the Institute for Health Metrics and Evaluation (IHME), Global Burden of Diseases, the prevalence of bipolar disorder across the world varies from 0.3 to 1.2% by country. In 2017 around 46 million people in the world had bipolar disorder, with 52% and 48% being female and male, respectively. The typical age of onset is the late teens or the early 20s, and a history of depression is common in people diagnosed with bipolar. Men and women are affected by bipolar disorder in equal numbers. In women, the first episode is typically manic, while men typically experience a depressive episode first. Hence, the rise in the cases of the disease and the increasing need to manage them effectively has led to the growth of the bipolar disorder market.

Scope of the Report

As per the scope of this report, bipolar disorder is a mental illness marked by extreme shifts in mood. Symptoms may include an extremely elevated mood called mania, and also episodes of depression. Bipolar disorder is also known as bipolar disease or manic depression. People with bipolar disorder may have trouble managing everyday life tasks at school or work, or maintaining relationships. There's no cure, but there are many treatment options available that can help with managing the symptoms.

Key Market Trends

Antipsychotic Drugs is expected to be the Fastest Growing Segment Over the Forecast Period

Antipsychotic medications are used as a short-term treatment for bipolar disorder to control psychotic symptoms, such as hallucinations, delusions, or mania symptoms. These symptoms may occur during acute mania or severe depression. Some also treat bipolar depression, and several have demonstrated long-term value in preventing future episodes of mania or depression. In people with bipolar disorder, antipsychotics are also used "off label" as sedatives, for insomnia, for anxiety, and/or for agitation. Often, they are taken with a mood-stabilizing drug and can decrease the symptoms of mania until mood stabilizers take full effect. Some antipsychotics seem to help stabilize moods on their own. As a result, they may be used alone as a long-term treatment for people who do not tolerate or respond to lithium and anticonvulsants. A few antipsychotic drugs include aripiprazole (Abilify), asenapine (Saphris), cariprazine (Vraylar), clozapine (Clozaril), lurasidone (Latuda), olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal), and ziprasidone (Geodon). Hence, due to the above-mentioned reasons, the market for antipsychotic drugs is expected to grow and further lead to the growth in the Bipolar Disorder Market.

North America is Expected to Dominate the Market

North America is found to hold a major share for the bipolar disorder market and is expected to show a similar trend over the forecast period, without significant fluctuations. Due to the increasing cases of bipolar disorder and the presence of better healthcare infrastructure, the market is expected to witness high growth over the forecast period. According to the data published by the National Alliance on Mental Illness, around 1 in 5 adults in the United States experiences mental illness in a given year. Hospitalization is required for severe episodes of mania and depression to protect the patients from injuring themselves or others. According to the NIMH, bipolar I disorder is characterized in part by manic symptoms that are so severe that the person needs immediate hospital care. There is a huge need to tackle bipolar disorder, as it is an increasing problem, and hence, the market for bipolar disorder is expected to grow during the forecast period.

Competitive Landscape

The market studied is a moderately consolidated market owing to the presence of small and large market players. Some of the market players are AbbVie Inc., Allergan PLC, AstraZeneca Plc, Eli Lilly and Company, GlaxoSmithKline Plc, Janssen Pharmaceuticals Inc., Novartis AG, Otsuka Holdings Co. Ltd, and Pfizer Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Bipolar Disorder
    • 4.2.2 Rising initiative by Government Institutes to Increase the Awareness
    • 4.2.3 Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 Side Effects Associated with Bipolar Drugs
    • 4.3.2 Misdiagnosis of Bipolar Disorder
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Mood stabilizer
    • 5.1.2 Anticonvulsant
    • 5.1.3 Antipsychotic Drug
    • 5.1.4 Antidepressant Drug
    • 5.1.5 Other
  • 5.2 By Mechanism of Action
    • 5.2.1 Selective Serotonin Reuptake Inhibitor
    • 5.2.2 Serotonin Norepinephrine Reuptake Inhibitor
    • 5.2.3 Tricyclic Antidepressant Drug
    • 5.2.4 Beta Blockers
    • 5.2.5 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 Allergan PLC
    • 6.1.3 AstraZeneca Plc
    • 6.1.4 Eli Lilly and Company
    • 6.1.5 GlaxoSmithKline Plc
    • 6.1.6 Janssen Pharmaceuticals Inc.
    • 6.1.7 Novartis AG
    • 6.1.8 Otsuka Holdings Co. Ltd
    • 6.1.9 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top